ONWARD Medical’s New ARC-IM Lumbar Lead: A Step Forward in Spinal Cord Stimulation Therapy
ONWARD Medical N.V., a pioneering medical technology company specializing in innovative spinal cord stimulation (SCS) therapies, recently announced the successful first human implant of its investigational ARC-IM Lumbar Lead. This second model in ONWARD’s ARC-IM Lead family is part of the company’s strategic plan to build a comprehensive portfolio of purpose-designed leads, aimed at optimizing the delivery of ARC-IM Therapy at various locations along the spinal cord.
Advancements in Spinal Cord Stimulation Therapy
The ARC-IM Lumbar Lead is a significant milestone in the development of ONWARD’s SCS therapies. SCS is a minimally invasive treatment that involves the delivery of electrical pulses to the spinal cord, which can help restore movement and other functions in individuals with spinal cord injuries (SCI) and other movement disabilities. By optimizing the design and placement of the leads, ONWARD aims to improve the efficacy and safety of the therapy.
A Portfolio of Purpose-Designed Leads
The ARC-IM Lumbar Lead is the latest addition to ONWARD’s growing portfolio of purpose-designed leads. This strategic move allows the company to tailor the therapy to specific areas of the spinal cord, offering the potential for more targeted and effective treatments. This approach could lead to better outcomes for patients, enabling them to regain more independence and improve their overall quality of life.
Impact on Individuals
For individuals with SCI or other movement disabilities, the advancements in SCS therapy, such as the ARC-IM Lumbar Lead, could mean a significant improvement in their daily lives. These innovations offer the potential for more targeted and effective treatments, which could lead to better functional outcomes and increased independence. For example, an individual with a lower spinal cord injury might benefit from a lumbar lead, as it can stimulate the areas of the spinal cord responsible for leg and trunk function.
Impact on the World
The advancements in SCS therapy, including the ARC-IM Lumbar Lead, have the potential to make a significant impact on the lives of millions of people worldwide. According to the World Health Organization, around 282,000 new cases of spinal cord injury occur each year. With innovative therapies like SCS and purpose-designed leads, there is hope for improving the lives of these individuals and reducing the burden of disability on both the individuals and society as a whole.
Conclusion
The first human implant of ONWARD Medical’s investigational ARC-IM Lumbar Lead represents an important step forward in the development of innovative spinal cord stimulation therapies. This purpose-designed lead is part of ONWARD’s strategic plan to build a comprehensive portfolio of leads, optimizing the delivery of ARC-IM Therapy at various locations along the spinal cord. The potential benefits of these advancements for individuals with spinal cord injuries or other movement disabilities are significant, offering the potential for more targeted and effective treatments, ultimately leading to improved functional outcomes and increased independence.
- ONWARD Medical announces the first human implant of the investigational ARC-IM Lumbar Lead
- ARC-IM Lumbar Lead is the second model in the ARC-IM Lead family
- Part of ONWARD’s strategic plan to build a portfolio of purpose-designed leads
- Optimizing the delivery of ARC-IM Therapy at various locations along the spinal cord
- Significant potential for individuals with spinal cord injuries or other movement disabilities
